These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Short-Term Effects of Gender-Affirming Hormone Therapy on Dysphoria and Quality of Life in Transgender Individuals: A Prospective Controlled Study. Foster Skewis L; Bretherton I; Leemaqz SY; Zajac JD; Cheung AS Front Endocrinol (Lausanne); 2021; 12():717766. PubMed ID: 34394009 [TBL] [Abstract][Full Text] [Related]
3. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). Cocchetti C; Castellini G; Iacuaniello D; Romani A; Maggi M; Vignozzi L; Schreiner T; den Heijer M; T'Sjoen G; Fisher AD J Sex Med; 2021 Apr; 18(4):821-829. PubMed ID: 33745831 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy. Karalexi MA; Frisell T; Cnattingius S; Holmberg D; Holmberg M; Kollia N; Skalkidou A; Papadopoulos FC Eur J Prev Cardiol; 2022 Nov; 29(15):2017-2026. PubMed ID: 35778824 [TBL] [Abstract][Full Text] [Related]
5. Metabolic and cardiovascular risks of hormone treatment for transgender individuals. de Silva NL; Dimakopoulou A; Quinton O; Jayasena CN Best Pract Res Clin Endocrinol Metab; 2024 Sep; 38(5):101907. PubMed ID: 38942618 [TBL] [Abstract][Full Text] [Related]
6. Estrogen-Based Gender-Affirming Hormone Therapy and Subclinical Cardiovascular Disease in Transgender Women with HIV. Martinez CA; Rikhi R; Fonseca Nogueira N; Pester MS; Salazar AS; Ashinne B; Aguilar N; Melara A; Porras V; Parker M; Mendez A; Cyrus E; De Santis JP; Jones DL; Brown TT; Hurwitz BE; Alcaide ML LGBT Health; 2023; 10(8):576-585. PubMed ID: 37459150 [No Abstract] [Full Text] [Related]
7. Gender-affirming hormone therapy and cardiovascular health in transgender adults. Ong C; Monita M; Liu M Climacteric; 2024 Jun; 27(3):227-235. PubMed ID: 38597210 [TBL] [Abstract][Full Text] [Related]
8. Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review. Spanos C; Bretherton I; Zajac JD; Cheung AS World J Diabetes; 2020 Mar; 11(3):66-77. PubMed ID: 32180895 [TBL] [Abstract][Full Text] [Related]
9. Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans. Hashemi L; Marijic Buljubasic A; Budoff MJ; Copeland LA; Jackson NJ; Jasuja GK; Gornbein J; Reue K JAMA Netw Open; 2024 Jul; 7(7):e2419696. PubMed ID: 38954413 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy. Hashemi L; Zhang Q; Getahun D; Jasuja GK; McCracken C; Pisegna J; Roblin D; Silverberg MJ; Tangpricha V; Vupputuri S; Goodman M J Sex Med; 2021 Sep; 18(9):1662-1675. PubMed ID: 34366264 [TBL] [Abstract][Full Text] [Related]
11. Gender-affirming hormone therapy induces specific DNA methylation changes in blood. Shepherd R; Bretherton I; Pang K; Mansell T; Czajko A; Kim B; Vlahos A; Zajac JD; Saffery R; Cheung A; Novakovic B Clin Epigenetics; 2022 Feb; 14(1):24. PubMed ID: 35177097 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population. Aranda G; Halperin I; Gomez-Gil E; Hanzu FA; SeguĂ N; Guillamon A; Mora M Front Endocrinol (Lausanne); 2021; 12():718200. PubMed ID: 34659112 [TBL] [Abstract][Full Text] [Related]
14. Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks. Sudhakar D; Huang Z; Zietkowski M; Powell N; Fisher AR Neurourol Urodyn; 2023 Jun; 42(5):903-920. PubMed ID: 36403287 [TBL] [Abstract][Full Text] [Related]
15. Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy. Shepherd R; Angus LM; Mansell T; Arman B; Kim BW; Lange K; Burgner D; Kerr JA; Pang K; Zajac JD; Saffery R; Cheung A; Novakovic B J Clin Endocrinol Metab; 2024 Oct; 109(11):2857-2871. PubMed ID: 38609170 [TBL] [Abstract][Full Text] [Related]
16. Ovarian, breast, and metabolic changes induced by androgen treatment in transgender men. Pirtea P; Ayoubi JM; Desmedt S; T'Sjoen G Fertil Steril; 2021 Oct; 116(4):936-942. PubMed ID: 34481638 [TBL] [Abstract][Full Text] [Related]
17. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study. Salakphet T; Mattawanon N; Manojai N; Muangmool T; Tangpricha V J Sex Med; 2022 May; 19(5):864-871. PubMed ID: 35379590 [TBL] [Abstract][Full Text] [Related]
18. Bone health and body composition in transgender adults before gender-affirming hormonal therapy: data from the COMET study. Ceolin C; Scala A; Dall'Agnol M; Ziliotto C; Delbarba A; Facondo P; Citron A; Vescovi B; Pasqualini S; Giannini S; Camozzi V; Cappelli C; Bertocco A; De Rui M; Coin A; Sergi G; Ferlin A; Garolla A; J Endocrinol Invest; 2024 Feb; 47(2):401-410. PubMed ID: 37450195 [TBL] [Abstract][Full Text] [Related]
19. Gender-affirming hormone therapy for transgender and gender-diverse adults in Australia. Nolan BJ; Cheung AS Intern Med J; 2024 Sep; 54(9):1450-1457. PubMed ID: 39056542 [TBL] [Abstract][Full Text] [Related]
20. Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy. Sanna E; Lami A; Giacomelli G; Alvisi S; Paccapelo A; Seracchioli R; Meriggiola MC Front Endocrinol (Lausanne); 2024; 15():1416121. PubMed ID: 39391880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]